Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Swedish Orphan Biovitrum AB (publ)
  6. News
  7. Summary
    SOBI   SE0000872095

SWEDISH ORPHAN BIOVITRUM AB (PUBL)

(SOBI)
  Report
Real-time Estimate Cboe Europe  -  10:41 2022-10-06 am EDT
221.70 SEK   +0.09%
09/30Sobi - New number of shares and votes in Swedish Orphan Biovitrum AB
AQ
09/30New number of shares and votes in Swedish Orphan Biovitrum AB (publ)
AQ
09/16ADC Therapeutics, Sobi Say CHMP Opinion Positive for Zynlonta for Relapsed or Refractory Diffuse Large B-cell Lymphoma
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Biovitrum AB - The Board of Directors exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under the incentive programme

07/19/2022 | 08:10am EDT

The Annual General Meeting of Swedish Orphan Biovitrum AB (publ) (Sobi) on 10 May 2022, resolved - for the purpose of ensuring that the company can fulfil its commitments under the long-term incentive programme resolved by the Annual General Meeting - on a directed share issue of no more than 2,690,287 redeemable and convertible class C shares.

The meeting also resolved to authorise the Board of Directors to resolve on the repurchase of all issued class C shares by an offer directed to all holders of class C shares. Repurchase under this authorisation may be made on one or several occasions until the Annual General Meeting 2023 and at a price of no less than 100 per cent and no more than 105 per cent of the quotient value of the share.

The Board of Directors has resolved to exercise the repurchase authorisation for the said purpose by repurchasing all issued class C shares against payment of 100 per cent of the quotient value of the share, corresponding to approximately SEK 0.55 per share. Repurchase of the class C shares may be effected during the period 19 July - 10 November 2022.

The company currently holds 11,258,569 own common shares and no own class C shares. Subsequently to the effected repurchase of class C shares above, all repurchased class C shares are intended to be converted to common shares, whereafter the number of own common shares will amount to 13,948,856.

Sobi

Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Providing sustainable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,600 employees across Europe, North America, the Middle East and Asia. In 2021, revenue amounted to SEK 15.5 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com, LinkedIn and YouTube.

Contact:

Swedish Orphan Biovitrum AB

Postal address SE-112 76 Stockholm

Sweden

Phone: 46 8 697 20 00

WEB: www.sobi.com

(C) 2022 Electronic News Publishing, source ENP Newswire

All news about SWEDISH ORPHAN BIOVITRUM AB (PUBL)
09/30Sobi - New number of shares and votes in Swedish Orphan Biovitrum AB
AQ
09/30New number of shares and votes in Swedish Orphan Biovitrum AB (publ)
AQ
09/16ADC Therapeutics, Sobi Say CHMP Opinion Positive for Zynlonta for Relapsed or Refractor..
MT
09/16Swedish Orphan Biovitrum, ADC Therapeutics Win Recommendation For Lymphoma Medication
MT
09/16ADC Therapeutics and Sobi Announce ZYNLONTA® (loncastuximab tesirine) Receives Positive..
CI
09/16ADC Therapeutics, Swedish Orphan Biovitrum's Co-Developed Drug Recommended for EU Autho..
DJ
09/16EU regulator backs wider use of AstraZeneca COVID therapy
RE
08/30FDA grants priority review to efanesoctocog alfa for people with haemophilia A
AQ
08/30Sanofi and Sobi Announce US Food and Drug Administration Accept Priority Review the Bio..
CI
07/21DRI Healthcare Trust Acquires Royalty Interest in Global Sales of Pegcetacoplan For US$..
MT
More news
Financials
Sales 2022 18 137 M 1 648 M 1 648 M
Net income 2022 2 344 M 213 M 213 M
Net Debt 2022 6 940 M 631 M 631 M
P/E ratio 2022 28,0x
Yield 2022 -
Capitalization 65 562 M 5 958 M 5 958 M
EV / Sales 2022 4,00x
EV / Sales 2023 3,55x
Nbr of Employees 1 554
Free-Float 57,8%
Chart SWEDISH ORPHAN BIOVITRUM AB (PUBL)
Duration : Period :
Swedish Orphan Biovitrum AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SWEDISH ORPHAN BIOVITRUM AB (PUBL)
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 221,50 SEK
Average target price 255,00 SEK
Spread / Average Target 15,1%
EPS Revisions
Managers and Directors
Guido Oelkers President & Chief Executive Officer
Henrik Stenqvist Chief Financial Officer
Sven Håkan Björklund Chairman
Sven Anders Ullman Chief Medical Officer, Head-Research & Development
Christine Wesström Head-Technical Operations
Sector and Competitors